SP7: from Bone Development to Skeletal Disease.


Journal

Current osteoporosis reports
ISSN: 1544-2241
Titre abrégé: Curr Osteoporos Rep
Pays: United States
ID NLM: 101176492

Informations de publication

Date de publication:
04 2023
Historique:
accepted: 18 01 2023
medline: 18 4 2023
pubmed: 8 3 2023
entrez: 7 3 2023
Statut: ppublish

Résumé

The purpose of this review is to summarize the different roles of the transcription factor SP7 in regulating bone formation and remodeling, discuss current studies in investigating the causal relationship between SP7 mutations and human skeletal disease, and highlight potential therapeutic treatments that targeting SP7 and the gene networks that it controls. Cell-type and stage-specific functions of SP7 have been identified during bone formation and remodeling. Normal bone development regulated by SP7 is strongly associated with human bone health. Dysfunction of SP7 results in common or rare skeletal diseases, including osteoporosis and osteogenesis imperfecta with different inheritance patterns. SP7-associated signaling pathways, SP7-dependent target genes, and epigenetic regulations of SP7 serve as new therapeutic targets in the treatment of skeletal disorders. This review addresses the importance of SP7-regulated bone development in studying bone health and skeletal disease. Recent advances in whole genome and exome sequencing, GWAS, multi-omics, and CRISPR-mediated activation and inhibition have provided the approaches to investigate the gene-regulatory networks controlled by SP7 in bone and the therapeutic targets to treat skeletal disease.

Identifiants

pubmed: 36881265
doi: 10.1007/s11914-023-00778-7
pii: 10.1007/s11914-023-00778-7
doi:

Substances chimiques

SP7 protein, human 0
Sp7 Transcription Factor 0

Types de publication

Journal Article Review Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

241-252

Subventions

Organisme : NIAMS NIH HHS
ID : K99 AR081897
Pays : United States
Organisme : NIDDK NIH HHS
ID : P01 DK011794
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007028
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK116716
Pays : United States

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Auteurs

Jialiang S Wang (JS)

Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. jwang101@mgh.harvard.edu.

Nicha Tokavanich (N)

Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Department of Developmental Biology, Harvard School of Dental Medicine, Boston, MA, USA.

Marc N Wein (MN)

Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Harvard Stem Cell Institute, Cambridge, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH